ArticleClinical journal of gastroenterology2026

Long-term survival after multidisciplinary treatment including durvalumab for recurrent perihilar cholangiocarcinoma.

Takashi Miyata et al.PubMed ↗Publisher ↗

No numbers read from the abstract.